Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Q Therapeutics' CFO and Vice President of Corporate Development, Steve Borst, Featured on theStockRadio.com

SALT LAKE CITY, UT -- (Marketwire) -- 01/02/13 -- Q Therapeutics, Inc., an emerging biotechnology company developing innovative cell therapy products for the treatment of debilitating diseases of the central nervous system, announced that theStockRadio.com has posted an audio interview conducted with the Company's CFO and Vice President of Corporate Development, Steve Borst.

To access the interview, please go to http://thestockradio.com/cfo-steven-borst-of-q-therapeutics-qcel/1914.

theStockRadio.com is a small-cap research and investment commentary provider. theStockRadio.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. Moreover, theStockRadio.com provides investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on theStockRadio.com, please visit http://thestockradio.com.

theStockRadio.com Disclosure
theStockRadio.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. theStockRadio.com is a Web site wholly owned by Allan James Group. Neither theStockRadio.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, theStockRadio.com, for complete risks and disclosures. To contact theStockRadio.com, please send an email to info@theStockRadio.com.

About Q Therapeutics, Inc.
Headquartered in Salt Lake City, Utah, Q Therapeutics, Inc. is a fully reporting, non-trading company, engaged in developing adult stem cell therapies to treat debilitating diseases of the central nervous system. The Company's first product, Q-Cells®, is a cell-based therapeutic intended to restore or preserve normal activity of neurons by providing essential support functions that occur in healthy central nervous system tissues. Q-Cells may be applicable to a wide range of central nervous system diseases, including demyelinating conditions such as multiple sclerosis, transverse myelitis, cerebral palsy and stroke; as well as other neurodegenerative diseases and injuries, such as ALS (Lou Gehrig's disease), spinal cord injury, Parkinson's disease and Alzheimer's disease. Q Therapeutics' initial clinical target is ALS, with a first IND submission expected in 2013. For more information, visit www.qthera.com.

Cautionary Statement Regarding Forward Looking Information
This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Q Therapeutics' technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of its intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Q Therapeutics' periodic reports, including the quarterly report on Form 10-Q for the period ended September 30, 2012 and the Company's Annual Report on Form 10-K for the year ended December 31, 2011.

Add to Digg Bookmark with del.icio.us Add to Newsvine

FOR MORE INFORMATION:
Hanover|Elite
Dodi Handy or Kathy Addison
407-585-1080
Email Contact

About Marketwired .
Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Web 2.0 Latest News
Mobile World Congress 2015 (MWC) has come and gone, but it seems like just yesterday when colleagues, customers, partners and competitors converged in the always beautiful city of Barcelona as it played host to the annual event. Amid the tapas, jamón and sangria, amazing advances in te...
Synergy Research reports that cloud infrastructure spending has been growing rapidly: “Cloud infrastructure is a fast-growing market and now accounts for almost half of all data center infrastructure shipments,” says Jeremy Duke, founder and Chief Analyst, Synergy Research. “We a...
In my new report titled Real-Time Mobile Infrastructure, I ask 80 IT and business professionals involved in enterprise mobility to answer a series of questions. The results will be shared here in the following article series.
The GoDaddy customer breaches didn’t have to happen and don’t have to happen to you. Cisco threat researchers recently reported a dramatic uptick in Angler Exploit Kit-based attacks connected to compromised GoDaddy domain registry accounts. GoDaddy, which manages nearly a third of al...
Like DDoS attacks, aggressive screen scraping can create huge spikes in traffic, cause brownouts, and even take you down for extended periods of time. Web scraping doesn’t make the headlines and most people aren’t aware of the damage it can cause to your website’s success. Thieves an...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE